BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37504317)

  • 1. Chemotherapy Regimens for Non-Metastatic Conventional Appendicular Osteosarcoma: A Literature Review Based on the Outcomes.
    Soares do Brito J; Santos R; Sarmento M; Fernandes P; Portela J
    Curr Oncol; 2023 Jun; 30(7):6148-6165. PubMed ID: 37504317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
    Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
    Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing pattern of relapse in osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy.
    Bacci G; Ruggieri P; Picci P; Briccoli A; Ferraro A; Ferrari S; Tienghi A; Iantorno D; Campanacci M
    J Chemother; 1995 Jun; 7(3):230-9. PubMed ID: 7562020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
    Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy for osteosarcoma.
    Eilber FR; Rosen G
    Semin Oncol; 1989 Aug; 16(4):312-22. PubMed ID: 2667146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection.
    Berend KR; Pietrobon R; Moore JO; Dibernardo L; Harrelson JM; Scully SP
    J Surg Oncol; 2001 Nov; 78(3):162-70. PubMed ID: 11745799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic implication of adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide in patients with extraskeletal osteosarcoma.
    Wakamatsu T; Kakunaga S; Takenaka S; Outani H; Hamada K; Imura Y; Hori Y; Naka N; Kudawara I; Yoshikawa H; Ueda T
    Int J Clin Oncol; 2019 Oct; 24(10):1311-1319. PubMed ID: 31197555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
    Yu W; Tang L; Lin F; Yao Y; Shen Z
    Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
    Bacci G; Briccoli A; Rocca M; Ferrari S; Donati D; Longhi A; Bertoni F; Bacchini P; Giacomini S; Forni C; Manfrini M; Galletti S
    Ann Oncol; 2003 Jul; 14(7):1126-34. PubMed ID: 12853357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: a network meta-analysis of randomized controlled trials.
    Wang X; Zheng H; Shou T; Tang C; Miao K; Wang P
    J Orthop Surg Res; 2017 Mar; 12(1):52. PubMed ID: 28356114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neoadjuvant treatment in osteosarcomas].
    Kalifa C; Brugières L; Le Deley MC
    Bull Cancer; 2006 Nov; 93(11):1115-20. PubMed ID: 17145581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
    Iwamoto Y; Tanaka K; Isu K; Kawai A; Tatezaki S; Ishii T; Kushida K; Beppu Y; Usui M; Tateishi A; Furuse K; Minamizaki T; Kawaguchi N; Yamawaki S
    J Orthop Sci; 2009 Jul; 14(4):397-404. PubMed ID: 19662473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes in Treatment-Naïve Patients With Metastatic Extremity Osteosarcoma Treated With OGS-12, a Novel Non-High-Dose Methotrexate-Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center.
    Bajpai J; Chandrasekharan A; Simha V; Talreja V; Karpe A; Pandey N; Singh A; Rekhi B; Vora T; Ghosh J; Banavali S; Gupta S
    J Glob Oncol; 2018 Sep; 4():1-10. PubMed ID: 30241240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Primary chemotherapy with the Rosen T10 protocol before conservative surgery in limb primitive osteosarcomas: results about 56 cases].
    Boussen H; Mezzi F; Gamoudi A; Daldoul O; Ben Hamida H; Mezlini A; Khalfallah S; Karray S; Ben Romdhane K; Ben Ghachem M; Ben Abdallah M; Douik M; Saadi A; Ben Ayed F; Ben Hassine H
    Bull Cancer; 2000 Feb; 87(2):183-8. PubMed ID: 10705289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro drug sensitivity (IDS) of patient-derived primary osteosarcoma cells as an early predictor of the clinical outcomes of osteosarcoma patients.
    Klangjorhor J; Phanphaisarn A; Teeyakasem P; Chaiyawat P; Phinyo P; Settakorn J; Theera-Umpon N; Pruksakorn D
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1165-1176. PubMed ID: 32476109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results after combined modality treatment for non-metastatic osteosarcoma.
    Aparicio J; Segura A; Montalar J; Garcerá S; Oltra A; Santaballa A; Yuste A; Pastor M; Munárriz B
    Med Oncol; 1999 Dec; 16(4):255-60. PubMed ID: 10618688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?
    Xu J; Xie L; Guo W
    Clin Orthop Relat Res; 2018 Nov; 476(11):2177-2186. PubMed ID: 29912746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases.
    Bacci G; Ferrari S; Ruggieri P; Biagini R; Fabbri N; Campanacci L; Bacchini P; Longhi A; Forni C; Bertoni F
    Acta Orthop Scand; 2001 Apr; 72(2):167-72. PubMed ID: 11372948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy.
    Hattinger CM; Michelacci F; Sella F; Magagnoli G; Benini S; Gambarotti M; Palmerini E; Picci P; Serra M; Ferrari S
    Histopathology; 2015 Sep; 67(3):338-47. PubMed ID: 25600168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging is appropriate for determining the osteotomy plane for appendicular osteosarcoma after neoadjuvant chemotherapy.
    Han G; Wang Y; Bi WZ; Wang DJ; Lu SB; Zhang L; Zhao B
    Med Oncol; 2012 Jun; 29(2):1347-53. PubMed ID: 21350876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.